US Stock MarketDetailed Quotes

AMRN Amarin

Watchlist
  • 0.542
  • -0.009-1.65%
Close Feb 28 16:00 ET
  • 0.553
  • +0.011+2.03%
Post 19:54 ET
222.90MMarket Cap-5.42P/E (TTM)

About Amarin Company

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Company Profile

SymbolAMRN
Company NameAmarin
Listing DateApr 1, 1993
Issue Price6.00
Founded1989
CEOMr. Aaron D. Berg
MarketNASDAQ
Employees275
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressIconic Offices, The Greenway,Block C Ardilaun Court, 112–114,St. Stephens Green
CityDublin
ProvinceDublin
CountryIreland
Zip Code2
Phone353-1-6699-020

Company Executives

  • Name
  • Position
  • Salary
  • Aaron D. Berg
  • Director, President and Chief Executive Officer
  • 2.45M
  • Jonathan N. Provoost
  • Executive Vice President, Chief Legal and Compliance Officer and Secretary
  • 659.26K
  • Peter Fishman
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Steven B. Ketchum, PhD
  • Executive Vice President, President, Research and Development and Chief Scientific Officer
  • 2.35M
  • Dr. Odysseas D. Kostas, M.D.
  • Chairman of the Board
  • 650.41K
  • Mark DiPaolo, Esq.
  • Independent Director
  • 621.00K
  • Dr. Paul Cohen, M.D.
  • Independent Director
  • 622.06K
  • Louis Sterling, III
  • Independent Director
  • 629.35K
  • Patrice Bonfiglio
  • Independent Director
  • 626.87K
  • Oliver O'Connor
  • Independent Director
  • 611.85K
  • Diane E. Sullivan
  • Independent Director
  • 630.83K
  • Keith L. Horn
  • Independent Director
  • 632.09K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More